Secukinumab demonstrates an acceptable safety profile in moderate to severe plaque psoriasis: Pooled analysis of 10 phase 2/3 studies

被引：0

作者：

Foley, P. ^{[1
]}

Griffiths, C. ^{[2
]}

Reich, K. ^{[3
]}

Leonardi, C. L. ^{[4
]}

Blauvelt, A. ^{[5
]}

Mehta, N. N. ^{[6
]}

Tsai, T. F. ^{[7
]}

Gong, Y. ^{[8
]}

Papavassilis, C. ^{[9
]}

Huang, J. ^{[8
]}

Fox, T. ^{[9
]}

van de Kerkhof, P. ^{[10
]}

机构：

[1] St Vincents Hosp, Dept Dermatol, Melbourne, Vic, Australia

[2] Univ Manchester, Manchester, Lancs, England

[3] SCIderm GmbH, Hamburg, Germany

[4] St Louis Univ, Sch Med, St Louis, MO USA

[5] Oregon Med Res Ctr, Portland, OR USA

[6] NHLBI, Sect Inflammat & Cardiometab Dis, Bldg 10, Bethesda, MD 20892 USA

[7] Natl Taiwan Univ, Coll Med, Natl Taiwan Univ Hosp, Taipei 10764, Taiwan

[8] Beijing Novartis Pharma Co Ltd, Beijing, Peoples R China

[9] Novartis Pharma AG, Basel, Switzerland

[10] Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands

来源：

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

引用

页码：50 / 50

页数：1